Multiple Myeloma
October 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Bortezomib-Induced Muscle Toxicity in Multiple Myeloma.
Authors:Guglielmi V, Nowis D, Tinelli M, Malatesta M, Paoli L, Marini M, Manganotti P, Sadowski R, Wilczynski GM, Meneghini V, Tomelleri G, Vattemi G
Institution:Department of Neurosciences, Biomedicine and Movement Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy; Genomic Medicine, Department of General, Transplant and Liver Surgery, Medical University of Warsaw and Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland; Department of Medicine, Hematology Section, University of Verona, Verona, Italy; Department of Neurosciences, Biomedicine and Movement Sciences, Section of Anatomy and Histology, University of Verona, Verona, Italy; Department of Immunology, Center for Biostructure Research, Medical University of Warsaw, Warsaw, Poland; and Laboratory of Molecular and Systemic Neuromorphology, Nencki Institute of Experimental Biology, Department of Neurophysiology Warsaw, Poland.
Journal:J Neuropathol Exp Neurol. 2017 Jul 1;76(7):620-630. doi: 10.1093/jnen/nlx043.

2:Pleural Effusion in Multiple Myeloma: Characteristics and Practice Patterns.
Authors:Byun JM, Kim KH, Choi IS, Park JH, Kim JS, Shin DY, Koh Y, Kim I, Yoon SS, Lim HJ
Institution:Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Journal:Acta Haematol. 2017;138(2):69-76. doi: 10.1159/000477793. Epub 2017 Aug 11.

3:Elderly patients with multiple myeloma: towards a frailty approach?
Authors:Zweegman S, Engelhardt M, Larocca A
Institution:aDepartment of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands bDepartment of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany cDepartment of Hematology, University of Torino, Torino, Italy.
Journal:Curr Opin Oncol. 2017 Sep;29(5):315-321. doi: 10.1097/CCO.0000000000000395.

4:Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
Authors:Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ
Institution:Division of Hematology, Mayo Clinic, Rochester, MN.
Journal:Blood. 2017 Sep 7;130(10):1198-1204. doi: 10.1182/blood-2017-05-782961. Epub 2017 Jul 6.

5:How I treat first relapse of myeloma.
Authors:Harousseau JL, Attal M
Institution:Groupe Confluent, Nantes, France; and.
Journal:Blood. 2017 Aug 24;130(8):963-973. doi: 10.1182/blood-2017-03-726703. Epub 2017 Jul 5.

6:Safety of ixazomib for the treatment of multiple myeloma.
Authors:Bonnet A, Moreau P
Institution:a Department of Hematology , University Hospital Hotel-Dieu , Nantes , France.
Journal:Expert Opin Drug Saf. 2017 Aug;16(8):973-980. doi: 10.1080/14740338.2017.1344212. Epub 2017 Jul 12.

7:Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Authors:Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S
Institution:Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY. Roudebush VA Medical Center, Indianapolis, IN. d'Investigations Cliniques 1427, Hopital Saint Louis Lariboisiere, Paris, France. University, Atlanta, GA. Rochester, NY. Pennsylvania, Philadelphia, PA. University, Atlanta, GA.
Journal:Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.

8:Recognition of early mortality in multiple myeloma by a prediction matrix.
Authors:Terebelo H, Srinivasan S, Narang M, Abonour R, Gasparetto C, Toomey K, Hardin JW, Larkins G, Kitali A, Rifkin RM, Shah JJ
Institution:Providence Cancer Center, Southfield, Michigan. Carolina.
Journal:Am J Hematol. 2017 Sep;92(9):915-923. doi: 10.1002/ajh.24796. Epub 2017 Jul 19.

9:Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Authors:Maharaj S, Chang S, Seegobin K, Serrano-Santiago I, Zuberi L
Institution:a Department of Internal Medicine , University of Florida College of Medicine , Jacksonville , FL , USA. Miami , FL , USA. Jacksonville , FL , USA. Jacksonville , FL , USA. Jacksonville , FL , USA.
Journal:Expert Rev Anticancer Ther. 2017 Jul;17(7):585-591. doi: 10.1080/14737140.2017.1330153. Epub 2017 May 23.

10:How is patient care for multiple myeloma advancing?
Authors:Genadieva Stavric S, Bonello F, Bringhen S, Boccadoro M, Larocca A
Institution:a Medical Faculty , University Hematology Clinic , Skopje , Macedonia.; b Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy.
Journal:Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19.

11:Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Authors:Lahuerta JJ, Paiva B, Vidriales MB, Cordon L, Cedena MT, Puig N, Martinez-Lopez J, Rosinol L, Gutierrez NC, Martin-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF
Institution:Juan-Jose Lahuerta, Maria-Teresa Cedena, Joaquin Martinez-Lopez, and Maria-Luisa Martin-Ramos, Hospital 12 de Octubre, CIBERONC; Raquel de Paz, Hospital Universitario La Paz; Rafael Martinez, Hospital Clinico San Carlos; Adrian Alegre, Hospital Universitario La Princesa, Madrid; Bruno Paiva and Jesus F. San-Miguel, Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona; Laura Rosinol, and Joan Blade, Hospital Clinic de Barcelona, Barcelona; Maria-Belen Vidriales, Noemi Puig, Norma C. Gutierrez, Alejandro Martin, and Maria-Victoria Mateos, Hospital Universitario de Salamanca Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigacion del Cancer (IBMCC-USAL, CSIC), CIBERONC; Alberto Orfao, Servicio General de Citometria-NUCLEOS, Centro de Investigacion del Cancer (IBMCC-USAL, CSIC), IBSAL and Department of Medicine, Universidad de Salamanca, CIBERONC, Salamanca; Lourdes Cordon and Javier De la Rubia, Hospital Universitario y Politecnico La Fe; Ana-Isabel Teruel, Hospital Clinico de Valencia, Valencia; Albert Oriol, Hospital Germans Trias i Pujol, Badalona; Maria-Asuncion Echeveste, Hospital de Donostia, San Sebastian; Felipe de Arriba, Hospital Morales Meseguer, Murcia; Miguel T. Hernandez, Hospital Universitario de Canarias, Tenerife; Luis Palomera, Hospital Universitario Lozano Blesa, Zaragoza, Spain.
Journal:J Clin Oncol. 2017 Sep 1;35(25):2900-2910. doi: 10.1200/JCO.2016.69.2517. Epub 2017 May 12.

12:The safety of daratumumab for the treatment of multiple myeloma.
Authors:Cejalvo MJ, Ribas P, de la Rubia J
Institution:a Hematology Service , University Hospital Doctor Peset , Valencia , Spain. "San Vicente Martir" , Valencia , Spain.
Journal:Expert Opin Drug Saf. 2017 Jun;16(6):753-760. doi: 10.1080/14740338.2017.1328053. Epub 2017 May 22.

13:Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Authors:Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hajek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG
Institution:Division of Hematology, Mayo Clinic, Rochester, MN, USA.; University Hospital Hotel Dieu, Nantes, France.; Division of Hematology and Oncology, Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, WI, USA.; Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain.; Wilhelminenspital der Stadt Wien, Vienna, Austria.
Journal:Br J Haematol. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9.

14:A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Authors:Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R
Institution:UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. University, Columbus, OH. York, NY. San Francisco, CA. San Francisco, CA. York, NY. Department of Medicine, Washington University, St. Louis, MO.
Journal:Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.

15:Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Authors:Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A
Institution:Levine Cancer Institute/Carolinas Health Care System, Charlotte, North Carolina. Belgium.
Journal:Am J Hematol. 2017 Aug;92(8):E146-E152. doi: 10.1002/ajh.24781. Epub 2017 Jun 5.

16:A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Authors:Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosinol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG
Institution:Dana-Farber Cancer Institute, Boston, MA, USA. Program, Vanderbilt University School of Medicine, Nashville, TN, USA. USA. (CIMA), Pamplona, Spain. Center, Houston, TX, USA. Charlotte, NC, USA. Molecular y Celular del Cancer, Hospital Universitario Salamanca, Universidad de Salamanca-Consejo Superior de Investigaciones Cientificas, Salamanca, Spain.
Journal:Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3.

17:Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Authors:Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z
Institution:University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Journal:Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.

18:Novel investigational drugs active as single agents in multiple myeloma.
Authors:D'Agostino M, Salvini M, Palumbo A, Larocca A, Gay F
Institution:a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy.; b Currently Takeda employee.
Journal:Expert Opin Investig Drugs. 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 May 8.

19:Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Authors:Aguiar PM, de Mendonca Lima T, Colleoni GWB, Storpirtis S
Institution:Department of Pharmacy, University of Sao Paulo, Sao Paulo, Brazil. Electronic address: aguiar.pm@usp.br. University of Sao Paulo, Sao Paulo, Brazil.
Journal:Crit Rev Oncol Hematol. 2017 May;113:195-212. doi: 10.1016/j.critrevonc.2017.03.014. Epub 2017 Mar 16.

20:Which therapies will move to the front line for multiple myeloma?
Authors:Cejalvo MJ, de la Rubia J
Institution:a Hematology Service , University Hospital Doctor Peset , Valencia , Spain. Martir" , Valencia , Spain.
Journal:Expert Rev Hematol. 2017 May;10(5):383-392. doi: 10.1080/17474086.2017.1317589. Epub 2017 Apr 24.

21:IgM myeloma: A multicenter retrospective study of 134 patients.
Authors:Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA
Institution:Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Jagiellonian University Medical College, Krakow, Poland.; Masaryk University, Brno, Czech Republic.; Professor Edgar Santos University Hospital, Salvador, Brazil.; University Hospital of Salamanca, Salamanca, Spain.
Journal:Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

22:Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
Authors:Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ
Institution:Division of Hematology & Oncology, The University of Nebraska Medical Center, Omaha, NE, USA.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rorlowski@mdanderson.org.; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rorlowski@mdanderson.org.
Journal:Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.

23:Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Authors:Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P
Institution:National and Kapodistrian University of Athens, Athens, Greece. University, Budapest, Hungary. Ostrava, Czech Republic. Plovdiv, Bulgaria.
Journal:Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17.

24:Monoclonal antibody therapy in multiple myeloma.
Authors:Touzeau C, Moreau P, Dumontet C
Institution:Service d'hematologie clinique, Nantes, France.
Journal:Leukemia. 2017 May;31(5):1039-1047. doi: 10.1038/leu.2017.60. Epub 2017 Feb 17.

25:Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Authors:Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H
Institution:Faculty of Medicine, University of Melbourne, Victoria, Australia. Australia. Australia. Zealand.
Journal:Br J Haematol. 2017 May;177(3):441-448. doi: 10.1111/bjh.14562. Epub 2017 Feb 15.

26:Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.
Authors:Rosinol L, Oriol A, Teruel AI, de la Guia AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, Gonzalez Y, Etxebeste M, Martinez-Martinez R, Hernandez MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martinez-Lopez J, Lahuerta JJ, San Miguel J, Blade J
Institution:Department of Hematology, Hospital Clinic de Barcelona, Barcelona, Spain. Spain. Spain. Spain. Madrid,Spain. Spain.
Journal:Leukemia. 2017 Sep;31(9):1922-1927. doi: 10.1038/leu.2017.35. Epub 2017 Jan 23.

27:Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Authors:Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J
Institution:Cardiovascular Division, Vanderbilt University School of Medicine, Nashville, Tennessee2Cardio-Oncology Program,Vanderbilt University School of Medicine, Nashville, Tennessee3Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee. Nashville, Tennessee. Center, Vanderbilt University School of Medicine, Nashville, Tennessee. Tennessee2Cardio-Oncology Program,Vanderbilt University School of Medicine, Nashville, Tennessee3Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Journal:JAMA Oncol. 2017 Jul 1;3(7):980-988. doi: 10.1001/jamaoncol.2016.3350.

28:Physical Activity Preferences for People Living With Multiple Myeloma: A Qualitative Study.
Authors:Craike M, Hose K, Courneya KS, Harrison SJ, Livingston PM
Institution:Author Affiliations: Institute of Sport, Exercise and Active Living (ISEAL), Victoria University, Melbourne, Australia (Dr Craike); Austin Health, Heidelberg, Australia (Ms Hose); Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Canada (Dr Courneya); Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia (Dr Harrison); and Deakin University, Geelong, Australia, Faculty of Health (Dr Livingston).
Journal:Cancer Nurs. 2017 Sep/Oct;40(5):E1-E8. doi: 10.1097/NCC.0000000000000425.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount


Medifocus Guidebook on Multiple Myeloma

Updated: June 21, 2017
188 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MM72660854

Coupon Expires: November 17, 2017



What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
K.J.
Milwaukee, Wisconsin


"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
J.M.
New York, New York


"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
D.S.
Miami Beach, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.